ReviewACS pharmacology & translational science2024
Advancements in the Treatment of Atherosclerosis: From Conventional Therapies to Cutting-Edge Innovations.
Review in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Serum/glucocorticoid-regulated kinase 1 regulates vascular inflammation in atherosclerosis.Acta pharmacologica Sinica · 2026Article
- Paeonol attenuates atherosclerosis by inhibiting mTORJournal of translational internal medicine · 2026Article
- Targeting the Gut-Heart Axis in Atherosclerosis: Microbial Metabolites, Molecular Mechanisms, and Precision Therapeutics.Probiotics and antimicrobial proteins · 2026Review
- Review
- Cholesterol-depleted macrophage membrane-coated nano-rapamycin for targeted atherosclerosis therapy.Journal of nanobiotechnology · 2026Article
- Ginsenoside Re regulates PFKFB3-mediated glycolysis to inhibit endothelial cell migration to ameliorate atherosclerosis.Journal of ginseng research · 2026Article
- A Comprehensive Review of Epigenetic Regulation of Vascular Smooth Muscle Cells During Development and Disease.Biomolecules · 2026Review
- Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances.Cardiovascular therapeutics · 2026Review
- Saffron as a natural modulator of reverse cholesterol transport genes in atherosclerotic rabbits, with molecular docking insights.Scientific reports · 2025Article
- Advances in the treatment of atherosclerotic plaque based on nanomaterials.Nanomedicine (London, England) · 2025Review
- Unraveling atherosclerosis through single-cell RNA sequencing: insights into cellular heterogeneity and disease mechanisms.Einstein (Sao Paulo, Brazil) · 2025Review
- Advances in cardiovascular gene therapy: a systematic review of nanoparticle-based delivery strategies for atherosclerosis.American journal of cardiovascular disease · 2025Review
- β-sitosterol alleviated HFD-induced atherosclerosis by regulating the MAPK/Nrf2/NLRP3 pathway in ApoE-/- mice.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a leading cause of morbidity and mortality worldwide, driven by a complex interplay of lipid dysregulation, inflammation, and vascular pathology. Despite advancements in understanding the multifactorial nature of atherosclerosis and improvements in clinical management, existing therapies often fall short in reversing the disease, focusing instead on symptom alleviation and risk reduction. This review highlights recent strides in identifying genetic markers, elucidating inflammatory pathways, and understanding environmental contributors to atherosclerosis. It also evaluates the efficacy and limitations of current pharmacological treatments, revascularization techniques, and the impact of these interventions on patient outcomes. Furthermore, we explore innovative therapeutic strategies, including the promising fields of nanomedicine, nucleic acid-based therapies, and immunomodulation, which offer potential for targeted and effective treatment modalities. However, integrating these advances into clinical practice is challenged by regulatory, economic, and logistical barriers. This review synthesizes the latest research and clinical advancements to provide a comprehensive roadmap for future therapeutic strategies and emphasize the critical need for innovative approaches to fundamentally change the course of atherosclerosis management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.